Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

Over the past decade, the rising cost of insulin epitomized the broader systemic issue of higher healthcare out-of-pocket ...

The company granted stock options to purchase an aggregate of 208,350 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 272,850 shares of Nurix common ...

Investing.com -- L’Oreal SA (EPA: OREP) shares were downgraded to Equal Weight from Overweight by Morgan Stanley (NYSE: MS) ...

Sanofi (NASDAQ:SNY – Free Report) by 25.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 314,180 shares of the company’s stock ...

Investors fled the company's stock in 2024 as a slow US launch of Leqembi, the Alzheimer's disease drug it sells with Japan's ...

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity? The post What are brokers saying about ...

and also after the France-headquartered group issued a surprise rise in R&D spending accompanied by a profit warning in October that saw its share price come under pressure. Sanofi CEO Paul Hudson ...

The Melbourne-based company on Tuesday posted what chief executive Paul McKenzie described as a robust set of half-year ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...